How can cisplatin-induced nephrotoxicity be prevented or mitigated?

Cisplatin Nephrotoxicity Prevention and Mitigation

Aggressive intravenous hydration with saline is the cornerstone of cisplatin nephrotoxicity prevention, and amifostine may be considered in select patients with advanced ovarian or non-small cell lung cancer receiving repeated cisplatin doses. 1

Primary Prevention Strategy: Hydration

Adequate intravenous hydration before and after cisplatin administration is essential for all patients. 1 The FDA label explicitly states that cisplatin should be administered using a 6-8 hour infusion with intravenous hydration and mannitol to reduce nephrotoxicity. 2

Specific Hydration Protocols

• Administer adequate amounts of intravenous fluids prior to receiving and after receiving each cycle of cisplatin to prevent renal toxicity 1
• Patients often require intravenous fluids for 5-7 days in the outpatient setting after chemotherapy to prevent or treat dehydration 1
• Short-duration, low-volume outpatient hydration regimens appear safe and feasible, even for intermediate to high-dose cisplatin 3

The NCCN guidelines emphasize that giving intravenous hydration before and after intraperitoneal chemotherapy is a useful strategy to prevent nausea, vomiting, electrolyte imbalances, metabolic toxicities, and renal toxicity. 1

Pharmacologic Nephroprotection: Amifostine

Amifostine may be considered for prevention of nephrotoxicity in patients receiving cisplatin-based chemotherapy, specifically those with advanced ovarian cancer or non-small cell lung cancer. 1

Critical Limitations of Amifostine Use

The ASCO guidelines provide important restrictions on amifostine use:

• FDA approval is limited to reducing cumulative renal toxicity with repeated cisplatin administration in advanced ovarian cancer or non-small cell lung cancer 1
• Amifostine should NOT be administered in settings where chemotherapy can produce significant survival advantage or cure, except in clinical trials 1
• There are only limited data on amifostine's effects on chemotherapy efficacy in other settings 1
• Results do not suggest that cisplatin-based chemotherapy effectiveness is altered by amifostine 1

This represents a critical clinical decision point: amifostine is reserved for palliative settings where cure is not the goal, as its potential interference with chemotherapy efficacy in curative settings remains undefined.

Mannitol-Induced Forced Diuresis

Mannitol may be added to hydration protocols, particularly for high-dose cisplatin or patients with preexisting hypertension. 3 The FDA label indicates that cisplatin administration using a 6-8 hour infusion with intravenous hydration and mannitol has been used to reduce nephrotoxicity, though renal toxicity can still occur. 2

Recent systematic review evidence (2025) suggests preliminary trends that mannitol might reduce severe acute kidney injury versus placebo, though this is based on only three small trials (n=164) and should be considered hypothesis-generating rather than definitive. 4 The evidence remains insufficient for routine clinical implementation. 4

Magnesium Supplementation

Magnesium supplementation (8-16 milliequivalents) may limit cisplatin-induced nephrotoxicity. 3 This represents an evidence-based best practice principle for safe cisplatin use, though it is not mentioned in the primary ASCO or NCCN guidelines. 3

Patient Selection and Monitoring

Baseline Requirements

Patients must have normal renal function before starting cisplatin-based regimens. 1 The FDA label explicitly contraindicates cisplatin in patients with pre-existing renal impairment. 2

For intraperitoneal cisplatin regimens specifically:

• Normal renal function is mandatory 1
• Medically appropriate performance status based on anticipated toxicities 1
• No preexisting medical problems that could worsen (e.g., preexisting neuropathy) 1

Monitoring Protocol

Monitor renal function carefully after each cycle for myelosuppression, dehydration, electrolyte loss, and end-organ toxicities (renal and hepatic damage). 1 The FDA label specifies that renal function must return to normal before another dose of cisplatin can be given. 2

Dose Modifications for Renal Impairment

For patients with borderline renal function or minimal dysfunction, split-dose cisplatin administration may be considered (such as 35 mg/m² on days 1 and 2, or days 1 and 8), though the relative efficacy of cisplatin-containing combinations with such modifications remains undefined (category 2B). 1

Estimate glomerular filtration rate (GFR) to assess eligibility for cisplatin in patients with borderline renal function. 1 For patients with GFR <60 mL/min, carboplatin may be substituted for cisplatin, though carboplatin should not be substituted in the perioperative setting. 1

Common Pitfalls and Caveats

Elderly Patients

Elderly patients are more susceptible to nephrotoxicity than younger patients. 2 Cisplatin is substantially excreted by the kidney, and because elderly patients are more likely to have decreased renal function, care should be taken in dose selection and renal function monitoring. 2

Inadvertent Overdose Prevention

Exercise extreme caution to prevent inadvertent cisplatin overdose. 2 Doses greater than 100 mg/m²/cycle once every 3-4 weeks are rarely used. 2 Care must be taken to avoid confusion with carboplatin or prescribing practices that fail to differentiate daily doses from total dose per cycle. 2

Nephrotoxicity Characteristics

The FDA label describes cisplatin nephrotoxicity as:

• Dose-related and cumulative, representing the major dose-limiting toxicity 2
• Occurring in 28-36% of patients treated with a single 50 mg/m² dose 2
• First noted during the second week after dosing 2
• Manifested by elevations in BUN, creatinine, serum uric acid, and/or decreased creatinine clearance 2
• Becoming more prolonged and severe with repeated courses 2
• Associated with renal tubular damage 2

Drug Interactions Affecting Nephrotoxicity Risk

The risk of nephrotoxicity increases with concurrent use of other nephrotoxic agents. 1 The "triple whammy" combination of renin-angiotensin system inhibitors, diuretics, and nonsteroidal anti-inflammatory drugs is associated with increased acute kidney injury risk. 1